Prosperity Capital Advisors’s iShares Genomics Immunology and Healthcare ETF IDNA Stock Holding History

Prosperity Capital Advisors’s Portfolio IDNA Stock Details IDNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$597K	Sell	17,680 -3,528	-17%	-$106K	0.03%	253
2026 Q1	$616K	Sell	21,208 -2,804	-12%	-$81.4K	0.04%	248
2025 Q4	$629K	Sell	24,012 -502	-2%	-$12.9K	0.04%	223
2025 Q3	$579K	Buy	24,514 +2,228	+10%	+$49.3K	0.03%	259
2025 Q2	$457K	Buy	22,286 +4,798	+27%	+$96.6K	0.03%	273
2025 Q1	$349K	Buy	17,488 +3,085	+21%	+$68.9K	0.03%	274
2024 Q4	$326K	Sell	14,403 -288	-2%	-$6.92K	0.03%	271
2024 Q3	$362K	Buy	14,691 +1,058	+8%	+$25.8K	0.03%	249
2024 Q2	$315K	Buy	13,633 +1,792	+15%	+$41.9K	0.03%	240
2024 Q1	$285K	Buy	11,841 +182	+2%	+$4.27K	0.03%	271
2023 Q4	$268K	Buy	+11,659	New	+$234K	0.03%	210

Other funds holding IDNA

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return

WBG

Wharton Business Group Malvern, Pennsylvania $2.99B AUM 30.41% 1-Year Est. Return

Jane Street New York $1.21T AUM 78.12% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $495B AUM 43.24% 1-Year Est. Return

PGA

Portland Global Advisors Portland, Maine $1.05B AUM 18.22% 1-Year Est. Return

Wells Fargo San Francisco, California $617B AUM 30.33% 1-Year Est. Return

Trek Financial Scottsdale, Arizona $2.01B AUM 53.49% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Prosperity Capital Advisors's IDNA Position: Q2 2026 in Review

Prosperity Capital Advisors reduced its iShares Genomics Immunology and Healthcare ETF (IDNA) stake by 17% in Q2 2026, selling an estimated $106K and leaving 17,680 shares worth $597K. The position accounts for 0.03% of the portfolio, ranked #253.

Prosperity Capital Advisors first reported a position in IDNA in Q4 2023 and has held it in 11 quarters since. The position peaked at $629K in Q4 2025. 66 funds tracked by Wall St. Rank hold IDNA as of Q2 2026.

Prosperity Capital Advisors held 17,680 shares of iShares Genomics Immunology and Healthcare ETF worth $597K as of Q2 2026.
Prosperity Capital Advisors sold 3,528 iShares Genomics Immunology and Healthcare ETF shares in Q2 2026, an estimated $106K.
iShares Genomics Immunology and Healthcare ETF made up 0.03% of Prosperity Capital Advisors's portfolio in Q2 2026, its #253 holding.
Prosperity Capital Advisors first reported a position in iShares Genomics Immunology and Healthcare ETF in Q4 2023 and has held it in 11 quarters since.
Prosperity Capital Advisors's iShares Genomics Immunology and Healthcare ETF position peaked at $629K in Q4 2025.
66 funds tracked by Wall St. Rank held iShares Genomics Immunology and Healthcare ETF as of Q2 2026.

Based on Prosperity Capital Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.